| Literature DB >> 35106564 |
Anna Dal Molin1, Enrico Gaffo1, Valeria Difilippo2, Alessia Buratin1,2, Caterina Tretti Parenzan3,4, Silvia Bresolin3,4, Stefania Bortoluzzi1,5.
Abstract
Circular RNAs (circRNAs), transcripts generated by backsplicing, are particularly stable and pleiotropic molecules, whose dysregulation drives human diseases and cancer by modulating gene expression and signaling pathways. CircRNAs can regulate cellular processes by different mechanisms, including interaction with microRNAs (miRNAs) and RNA-binding proteins (RBP), and encoding specific peptides. The prediction of circRNA functions is instrumental to interpret their impact in diseases, and to prioritize circRNAs for functional investigation. Currently, circRNA functional predictions are provided by web databases that do not allow custom analyses, while self-standing circRNA prediction tools are mostly limited to predict only one type of function, mainly focusing on the miRNA sponge activity of circRNAs. To solve these issues, we developed CRAFT (CircRNA Function prediction Tool), a freely available computational pipeline that predicts circRNA sequence and molecular interactions with miRNAs and RBP, along with their coding potential. Analysis of a set of circRNAs with known functions has been used to appraise CRAFT predictions and to optimize its setting. CRAFT provides a comprehensive graphical visualization of the results, links to several knowledge databases, and extensive functional enrichment analysis. Moreover, it originally combines the predictions for different circRNAs. CRAFT is a useful tool to help the user explore the potential regulatory networks involving the circRNAs of interest and generate hypotheses about the cooperation of circRNAs into the modulation of biological processes.Entities:
Keywords: CircRNA; bioinformatics; computational pipeline; functional prediction; regulatory network
Mesh:
Substances:
Year: 2022 PMID: 35106564 PMCID: PMC8921651 DOI: 10.1093/bib/bbab601
Source DB: PubMed Journal: Brief Bioinform ISSN: 1467-5463 Impact factor: 11.622
CircRNAs used for the CRAFT assessment analysis, with previously validated functional elements and biological or pathogenetic roles
| CircRNA | Backsplice | Validated functional element | Validated interaction/peptide (aa) | CircRNA binding validation | Tissue | Function | Reference |
|---|---|---|---|---|---|---|---|
| circBCRC3 | 2:231075511–231087181:+ | MRE | miR-182-5p | Biotin-labeled RNA pulldown assay, FISH, transfection | Bladder cancer | Tumor suppressor | [ |
| circHIPK3 | 11:33286413-33287511:+ | MRE | miR-124-3p | Luciferase reporter assay, biotin-labeled miRNA pulldown assay | Liver cancer | Oncogenic | [ |
| circHIPK3 | 11:33286413-33287511:+ | MRE | miR-653-5p, miR-338-3p | RIP assay, luciferase reporter assay, biotin-labeled miRNA pulldown assay | Gastric cancer | Oncogenic | [ |
| circNR3C1 | 5:143399656–143400852:- | MRE | miR-27a-3p | Biotin-labeled miRNA pulldown assay, FISH | Bladder cancer | Tumor suppressor | [ |
| circNRIP1 | 21:15014344–15043574:- | MRE | miR-149-5p | Biotin-labeled RNA pulldown assay, biotin-labeled miRNA assay, dual-luciferase reporter assay, FISH, qRT-PCR | Gastric cancer | Oncogenic | [ |
| circRNF20 | 9:101540203–101540975:+ | MRE | miR-487a | Luciferase reporter assay, FISH | Breast cancer | Oncogenic | [ |
| circSHKBP1 | 19:40583398–40583717:+ | MRE | miR-582-3p | Luciferase reporter assay, biotin-labeled RNA pulldown assay, FISH, qRT-PCR | Gastric cancer | Oncogenic | [ |
| circZNF609 | 15:64499292-64500166:+ | MRE | miR-15a-5p, miR-15b-5p | RNA pulldown assay, luciferase reporter assay | Hepatocellular carcinoma | Oncogenic | [ |
| circZNF609 | 15:64499292-64500166:+ | MRE | miR-138-5p | Luciferase reporter assay, RIP assay | Renal carcinoma | Oncogenic | [ |
| circDCUN1D4 | 4:51863437–51886638:+ | RRE | HuR(ELAVL1) | CLIP, RIP assay, biotin RNA pulldown assay, Western blot | Lung adenocarcinoma | Tumor suppressor | [ |
| circHIPK3 | 11:33340968–33341686:+ | RRE | FUS | Western blot, correlation analysis, knockdown, qRT-PCR | Cervical cancer | Oncogenic | [ |
| circMBNL1 | 3:152299405–152300367:+ | RRE | MBNL1 | RIP assay | Neuronal tissues | Gene regulator, circRNA biogenesis | [ |
| circNSUN2 | 5:6623214–6625669:- | RRE | IGF2BP2 | RNA pulldown assay, RIP, IF-FISH | Colorectal carcinoma | Oncogenic | [ |
| circPABPN1 | 14:23324138–23324289:+ | RRE | HuR(ELAVL1) | RIP, CLIP, biotin RNA pulldown assay | Cervical carcinoma | Negative regulation of PABPN1 mRNA and tanslation inibition/endogenous competing RNA | [ |
| circRHOBTB3 | 5:95755396–95763620:+ | RRE | HuR(ELAVL1) | RNA pulldown assay, RNA immunoprecipitation assays | Colorectal cancer | Tumor suppressor | [ |
| circSMARCA5 | 4:143543509-143543972:+ | RRE | SRSF1 | eCLIP | Glioblastoma multiforme | Tumor suppressor | [ |
| circXIAP | X:123888619–123892773:+ | RRE | FUS | Mass spectrometry analysis, RNA pull-down assay | Prostate cancer | Oncogenic | [ |
| circZKSCAN1 | 7:100023419–100024307:+ | RRE | FMRP(FMR1) | RIP assay | Hepatocellular carcinoma | Tumor suppressor | [ |
| circ-E-Cad | 16:68811684–68815759:+ | ORF | 254 | Monoclonal antibody, MS | Glioblastoma | Oncogenic | [ |
| circFNDC3B | 3:172247533–172251541:+ | ORF | 218 | LC–MS/MS | Colon cancer | Tumor suppressor | [ |
| circPLCE1 | 10:94030683–94032252:+ | ORF | 411 | LC–MS | Colorectal carcinoma | Tumor suppressor | [ |
| circSHPRH | 6:145888020–145894977:- | ORF | 146 | Antibody, LC–MS/MS | Glioblastoma | Tumor suppressor | [ |
| circSMO | 7:129205203–129206587:+ | ORF | 193 | Ribosomes enrichment assay, immunoblot (IB), MS | Glioblastoma | Oncogenic | [ |
| circZNF609 | 15:64499292–64500166:+ | ORF | 251 | Polysome association, western blot | Muscle | Implied in myogenesis | [ |
*CircRNAs used to illustrate CRAFT output. MRE, miRNA recognition element; RRE, RBP recognition element; ORF, open reading frame. Is near to the circRNAs used to illustrate CRAFT output. MRE, miRNA recognition element; RRE, RBP recognition element; ORF, open reading frame.
Figure 1CRAFT workflow, schematizing the pipeline input, the main analysis steps and the produced output.
Figure 2Assessment analysis of circRNAs with known functions. (A) The upper panel shows the number of validated circRNA-miRNA interactions detected by different methods and combinations thereof for each of the considered circRNAs, whereas the line plot below reports the sensitivity and the prediction ratio in the same conditions (M, miRanda; P, PITA; M | P, union of M and P; M & P, intersection of M and P; the same with AGO2, predicted sites overlapping with experimentally determined AGO2 binding sites); the right axis shows the mean number of predictions for circRNA; (B) the upper panel shows the number of validated circRNA-RBP interactions detected by different beRBP voteFrac thresholds, whereas the line plot below reports the sensitivity and the prediction ratio in the same conditions; the right axis shows the mean number of predictions for circRNA; (C) distribution of RBP binding site prediction scores for each circRNA (known binding sites are shown as orange points, the name is shown for the known site with the highest score; the percentage on the right indicates the prediction ratio of the corresponding voteFrac threshold); the notch boxplot on the right represents the distribution of the number of predicted RBP per circRNA at a certain voteFrac score; (D) barplot of the amino acid (aa) length of known (in green) and predicted (in red) peptides for each circRNA.
Figure 3The CircExtractor module of the CRAFT pipeline reconstructs the circRNA sequence using the backsplice coordinates and the genome annotation and reference. (A–D) show the four cases encompassed by the method, according to the position of the backplice ends (green and red triangles represent the backsplice start and end, respectively), in exonic (A–B), intronic (C) and intergenic sequences, and combinations thereof (D).
Figure 4CRAFT miRNA prediction output based on circZNF609 analysis. (A) Summary plot with predicted miRNA and RBP binding sites, and the longest ORF (with a stop codon), along the circRNA sequence; (B) table of CRAFT predicted miRNA binding sites in circZNF609 sequence, with start and end positions, and scores (orange and green boxes highlight predicted miR-15a-5p and miR-15b-5p binding sites, respectively); (C) table summarizing the number of TG per miRNA (box colors as in B); (D) plot of disease-miRNA TG association enrichment analysis; (E) network showing Reactome pathway enrichment analysis results on miRNA TG. In panels (B) and (C) only a small part of the corresponding table is shown.
Figure 5CRAFT RBP and ORF prediction output based on circZNF609 analysis. (A) Table of CRAFT predicted RBP binding sites in circZNF609 sequence, with start position, binding probability and prediction score; (B) plot of Reactome enrichment analyses on RBP potentially interacting with circZNF609, according to CRAFT predictions; (C) barplot of RBP-disease associations; (D) plot of the longest predicted ORF with a stop codon in circZNF609 sequence; (E) table with start and end position, length and frame of predicted ORF. In panels (A) and (E) only a small part of the corresponding table is shown.
Figure 6Predictions of different circRNAs are combined to facilitate hypothesis generation. (A) Heatmap of the miRNAs common to at least two circRNAs, considering the top 45% high-scoring miRNA binding site predictions; (B) network showing the 11 common validated TG, targeted by miR-1207-5p, miR-5581-3p and miR-611, respectively associated to circHIPK3 (the first) and circZNF609 (the last two); high-scoring predictions was obtained with miRanda score > 122 and energy < −24, PITA ΔGduplex < −20 and ΔGopen > −11; (C) heatmap of the RBP common to at least two circRNAs, considering the top 10% high-scoring RBP binding site predictions; (D) summary barplot of the number of ORF predicted for the group of circRNAs considered by CRAFT, binning ORF by the presence or absence of a stop codon in the reading frame. Canberra distance-based clustering has been used for heatmaps in (A) and (C).